Á¦ 9ȸ ¼±Ãµ¼º½ÉÀ庴 ½ÉÆ÷Áö¾ö : 2023-12-02
±³À°ÀÏÀÚ : 2023-12-02
±³À°Àå¼Ò : ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç
±³À°ÁÖÁ¦ : Á¦ 9ȸ ¼±Ãµ¼º½ÉÀ庴 ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ¼¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ±Ç¼öÁø
¿¬¶ôó : 02-3010-5700
À̸ÞÀÏ : iloveheart@amc.seoul.kr
±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú, ÈäºÎ¿Ü°ú
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ï : 5¸¸¿ø, ÇöÀåµî·Ï : 6¸¸¿ø, ¿ø³» ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 10:00~10:20 State of the art medical management of end stage heart failure in pediatric population ±èÁ¤À±(ºÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 10:20~10:40 Listing of children with end-stage heart failure: When and how? º¯Á¤Èñ(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 10:40~11:00 KONOS criteria of recipient status for pediatric heart transplantation ±èÀοÁ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 11:00~11:20 Adequate donor in pediatric heart transplantation ¼ÛÁø¿µ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 11:20~11:40 Managements for the sensitized patient awaiting heart transplantation ÇöÁØÈ£(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 11:40~12:00 Discussion ()
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 13:30~13:50 Recent experiences of VAD for pediatric population in Korea ½ÅÀ¯¸²(½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 13:50~14:10 Matching of donor and recipient in pediatric heart transplantation ? Perspective of body size and ABO blood type Anne Dipchand (Hospital for Sick Children)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 14:10~14:30 Heart transplantation for children with Fontan failure Àüº¸¹è(°¸ª¾Æ»êº´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 14:30~14:50 Troubleshooting abnormal vascular anatomy during heart transplantation in patients with congenital heart disease ÃÖÀº¼®(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 14:50~15:10 Discussion ()
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 15:40~16:00 Diagnosis of allograft rejection after heart transplantation ÀÌ»óÀ±(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 16:00~16:20 Immunosuppressive therapy after heart transplantation in pediatric recipients with post-transplant diabetes mellitus, post-transplant lymphoproliferative disease, cardiac allograft vasculopathy, and/or chronic kidney disease. Anne Dipchand (Hospital for Sick Children)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 16:20~16:40 Impact of donor inherent atherosclerosis on the progression of CAV after pediatric heart transplantation in AMC À¯Á¤Áø(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 16:40~17:00 Rehabilitation after pediatric heart transplantation °íÀºÀç(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 12¿ù 02ÀÏ ¼¿ï¾Æ»êº´¿ø µ¿°ü ´ë°´ç 17:00~17:20 Discussion ()